Skip Nav Destination
1-3 of 3
Andris Elksnis, Tomas A Schiffer, Fredrik Palm, Yun Wang, Jing Cen, Kyril Turpaev, Anongnad Ngamjariyawat, Shady Younis, Suling Huang, Yu Shen, Ying Leng, Peter Bergsten, Tony Karlsborn, Nils Welsh, Xuan Wang
Clin Sci (Lond) (2021) 135 (19): 2243–2263.
Published: 08 October 2021
...Andris Elksnis; Tomas A Schiffer; Fredrik Palm; Yun Wang; Jing Cen; Kyril Turpaev; Anongnad Ngamjariyawat; Shady Younis; Suling Huang; Yu Shen; Ying Leng; Peter Bergsten; Tony Karlsborn; Nils Welsh; Xuan Wang The protein tyrosine kinase inhibitor imatinib is used in the treatment of various...
Includes: Supplementary data
Clin Sci (Lond) (2010) 118 (4): 241–247.
Published: 09 November 2009
...Dariush Mokhtari; Nils Welsh Altered tyrosine kinase signalling has been implicated in several diseases, paving the way for the development of small-molecule TKIs (tyrosine kinase inhibitors). TKIs such as imatinib, sunitinib and dasatinib are clinically used for treating chronic myeloid leukaemia...
Clin Sci (Lond) (2006) 111 (4): 233–249.
Published: 13 September 2006
..., is of major importance in the development of many haematological malignancies. An understanding of the mechanisms by which BCR - ABL contributes to the pathogenesis of chronic myeloid leukaemia led to the development of imatinib, the first of several tyrosine kinase inhibitors to enter clinical trials...